Phase II Study of Betaseron (βser17-Interferon) as Treatment of Advanced Malignant Melanoma
Antitumor Activity of Recombinant Human Tumor Necrosis Factor in Combination with Hyperthermia, Chemotherapy, or Immunotherapy
Inhibition of Suppressor-Cell Activity by Cyclophosphamide in Patients with Malignant Melanoma
Intracavitary Administration of Biological Agents
Expansion of Activated T-Lymphocytes in Patients Treated with Recombinant Interleukin 2
Inhibitory Effects of Alloimmune T Cells on the Generation of Cytolytic Responses of Lymphokine-Activated Killer Cells
Formation of Macrophage (M) Colony-Stimulating Factor by Murine Leukemia × Fibroblast Hybrid Cells
Monoclonal Antibody Therapy in Malignant Melanoma